This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Belmadani, A. Articles by Creppy, E.E. Search for Related Content PubMed PubMed Citation Articles by Belmadani, A. Articles by Creppy, E.E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB DIAZEPAM Social Bookmarking                         What's this?

High performance liquid chromatography with ultraviolet detection used for laboratory routine determination of fluvoxamine in human plasma

Laboratoire de Toxicologie, Unité de Formation et de Recherche des Sciences Pharmaceutiques, Université Bordeaux , 3 ter Place de la Victoire, 33000 Bordeaux Cedex

I. Combourieu

Laboratoire Centre Hospitalier Spécialisé Charles Perrens, 121 rue de la Béchade, 33076 Bordeaux Cedex, France

M. Bonini

Laboratoire de Toxicologie, Unité de Formation et de Recherche des Sciences Pharmaceutiques, Université Bordeaux , 3 ter Place de la Victoire, 33000 Bordeaux Cedex

E.E. Creppy

Laboratoire de Toxicologie, Unité de Formation et de Recherche des Sciences Pharmaceutiques, Université Bordeaux , 3 ter Place de la Victoire, 33000 Bordeaux Cedex

Fluvoxamine is an antidepressant drug introduced into the clinic in 1986. It acts by selectively inhibiting neuronal serotonin recapture. It can be quantified by several meth ods, including high performance liquid chromatography. The HPLC method used so far needs special equipment and has poor sensitivity. The technique is difficult and time consuming. An easier, quicker and more sensitive HPLC assay for the routine determination of fluvoxamine in human plasma has therefore been developed.

After alkalinisation and direct extraction by a mixture of n-hexane-isoamylic alcohol 985: 15 (v/v) of plasma samples, the organic phases were further extracted by HCl 0.1 N.

Thirty µL of the final extract (with loxapine as internal standard) were injected directly into a C-8 column with a mobile phase consisting of 370 mL acetonitrile, 0.4 mL diethylamine, 630 mL of distilled water, 25 mL pic B5. UV detection at 254 nm was used.

The whole process was completed in 40 min. The detec tion limit was 10 ng mL-1. No interference was found either with several benzodiazepines or with antidepres sant drugs commonly associated during treatments.

Key Words: fluoxetine • HPLC-UV • drug monitoring • toxico kinetic • human plasma.

Human & Experimental Toxicology, Vol. 14, No. 1, 34-37 (1995)
DOI: 10.1177/096032719501400108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Yao, K. L. Kunze, W. F. Trager, E. D. Kharasch, and R. H. Levy Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19 Drug Metab. Dispos., May 1, 2003; 31(5): 565 - 571. [Abstract] [Full Text] [PDF]